Literature DB >> 22623764

A short segment of the HIV-1 gp120 V1/V2 region is a major determinant of resistance to V1/V2 neutralizing antibodies.

Nicole A Doria-Rose1, Ivelin Georgiev, Sijy O'Dell, Gwo-Yu Chuang, Ryan P Staupe, Jason S McLellan, Jason Gorman, Marie Pancera, Mattia Bonsignori, Barton F Haynes, Dennis R Burton, Wayne C Koff, Peter D Kwong, John R Mascola.   

Abstract

Antibody PG9 is a prototypical member of a class of V1/V2-directed antibodies that effectively neutralizes diverse strains of HIV-1. We analyzed strain-specific resistance to PG9 using sequence and structural information. For multiply resistant strains, mutations in a short segment of V1/V2 resulted in gain of sensitivity to PG9 and related V1/V2 neutralizing antibodies, suggesting both a common mechanism of HIV-1 resistance to and a common mode of recognition by this class of antibodies.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22623764      PMCID： PMC3421697          DOI： 10.1128/JVI.00696-12

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  17 in total

1.  Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1.

Authors:  Marie Pancera; Jason S McLellan; Xueling Wu; Jiang Zhu; Anita Changela; Stephen D Schmidt; Yongping Yang; Tongqing Zhou; Sanjay Phogat; John R Mascola; Peter D Kwong
Journal:  J Virol       Date:  2010-06-10       Impact factor: 5.103

2.  Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1.

Authors:  Robert Pejchal; Laura M Walker; Robyn L Stanfield; Sanjay K Phogat; Wayne C Koff; Pascal Poignard; Dennis R Burton; Ian A Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-02       Impact factor: 11.205

3.  Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructs.

Authors:  Yuuei Shu; Sarah Winfrey; Zhi-Yong Yang; Ling Xu; Srinivas S Rao; Indresh Srivastava; Susan W Barnett; Gary J Nabel; John R Mascola
Journal:  Vaccine       Date:  2006-11-07       Impact factor: 3.641

4.  Mining the B cell repertoire for broadly neutralizing monoclonal antibodies to HIV-1.

Authors:  Peter D Kwong; John R Mascola; Gary J Nabel
Journal:  Cell Host Microbe       Date:  2009-10-22       Impact factor: 21.023

5.  Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop.

Authors:  Penny L Moore; Elin S Gray; Daniel Sheward; Maphuti Madiga; Nthabeleng Ranchobe; Zhong Lai; William J Honnen; Molati Nonyane; Nancy Tumba; Tandile Hermanus; Sengeziwe Sibeko; Koleka Mlisana; Salim S Abdool Karim; Carolyn Williamson; Abraham Pinter; Lynn Morris
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

6.  Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16.

Authors:  Katie J Doores; Dennis R Burton
Journal:  J Virol       Date:  2010-08-04       Impact factor: 5.103

7.  Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1.

Authors:  Xueling Wu; Zhi-Yong Yang; Yuxing Li; Carl-Magnus Hogerkorp; William R Schief; Michael S Seaman; Tongqing Zhou; Stephen D Schmidt; Lan Wu; Ling Xu; Nancy S Longo; Krisha McKee; Sijy O'Dell; Mark K Louder; Diane L Wycuff; Yu Feng; Martha Nason; Nicole Doria-Rose; Mark Connors; Peter D Kwong; Mario Roederer; Richard T Wyatt; Gary J Nabel; John R Mascola
Journal:  Science       Date:  2010-07-08       Impact factor: 47.728

8.  Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies.

Authors:  Ming Li; Feng Gao; John R Mascola; Leonidas Stamatatos; Victoria R Polonis; Marguerite Koutsoukos; Gerald Voss; Paul Goepfert; Peter Gilbert; Kelli M Greene; Miroslawa Bilska; Denise L Kothe; Jesus F Salazar-Gonzalez; Xiping Wei; Julie M Decker; Beatrice H Hahn; David C Montefiori
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

9.  Naturally occurring substitutions of conserved residues in human immunodeficiency virus type 1 variants of different clades are involved in PG9 and PG16 resistance to neutralization.

Authors:  Suzie Thenin; Emmanuelle Roch; Tanawan Samleerat; Thierry Moreau; Antoine Chaillon; Alain Moreau; Francis Barin; Martine Braibant
Journal:  J Gen Virol       Date:  2012-04-04       Impact factor: 3.891

10.  Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target.

Authors:  Laura M Walker; Sanjay K Phogat; Po-Ying Chan-Hui; Denise Wagner; Pham Phung; Julie L Goss; Terri Wrin; Melissa D Simek; Steven Fling; Jennifer L Mitcham; Jennifer K Lehrman; Frances H Priddy; Ole A Olsen; Steven M Frey; Phillip W Hammond; Stephen Kaminsky; Timothy Zamb; Matthew Moyle; Wayne C Koff; Pascal Poignard; Dennis R Burton
Journal:  Science       Date:  2009-09-03       Impact factor: 47.728
View more
  59 in total

1.  New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency.

Authors:  Nicole A Doria-Rose; Jinal N Bhiman; Ryan S Roark; Chaim A Schramm; Jason Gorman; Gwo-Yu Chuang; Marie Pancera; Evan M Cale; Michael J Ernandes; Mark K Louder; Mangaiarkarasi Asokan; Robert T Bailer; Aliaksandr Druz; Isabella R Fraschilla; Nigel J Garrett; Marissa Jarosinski; Rebecca M Lynch; Krisha McKee; Sijy O'Dell; Amarendra Pegu; Stephen D Schmidt; Ryan P Staupe; Matthew S Sutton; Keyun Wang; Constantinos Kurt Wibmer; Barton F Haynes; Salim Abdool-Karim; Lawrence Shapiro; Peter D Kwong; Penny L Moore; Lynn Morris; John R Mascola
Journal:  J Virol       Date:  2015-10-14       Impact factor: 5.103

2.  Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.

Authors:  Shilpa Patil; Rajesh Kumar; Suprit Deshpande; Sweety Samal; Tripti Shrivastava; Saikat Boliar; Manish Bansal; Nakul Kumar Chaudhary; Aylur K Srikrishnan; Kailapuri G Murugavel; Suniti Solomon; Melissa Simek; Wayne C Koff; Rajat Goyal; Bimal K Chakrabarti; Jayanta Bhattacharya
Journal:  J Virol       Date:  2016-01-13       Impact factor: 5.103

3.  Structural basis for HIV-1 neutralization by 2F5-like antibodies m66 and m66.6.

Authors:  Gilad Ofek; Brett Zirkle; Yongping Yang; Zhongyu Zhu; Krisha McKee; Baoshan Zhang; Gwo-Yu Chuang; Ivelin S Georgiev; Sijy O'Dell; Nicole Doria-Rose; John R Mascola; Dimiter S Dimitrov; Peter D Kwong
Journal:  J Virol       Date:  2013-12-11       Impact factor: 5.103

4.  Sensitivity to Broadly Neutralizing Antibodies of Recently Transmitted HIV-1 Clade CRF02_AG Viruses with a Focus on Evolution over Time.

Authors:  Karl Stefic; Mélanie Bouvin-Pley; Asma Essat; Clara Visdeloup; Alain Moreau; Cécile Goujard; Marie-Laure Chaix; Martine Braibant; Laurence Meyer; Francis Barin
Journal:  J Virol       Date:  2019-01-04       Impact factor: 5.103

Review 5.  Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design.

Authors:  Dennis R Burton; Lars Hangartner
Journal:  Annu Rev Immunol       Date:  2016-05-20       Impact factor: 28.527

6.  Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers.

Authors:  Emilia Falkowska; Khoa M Le; Alejandra Ramos; Katie J Doores; Jeong Hyun Lee; Claudia Blattner; Alejandro Ramirez; Ronald Derking; Marit J van Gils; Chi-Hui Liang; Ryan Mcbride; Benjamin von Bredow; Sachin S Shivatare; Chung-Yi Wu; Po-Ying Chan-Hui; Yan Liu; Ten Feizi; Michael B Zwick; Wayne C Koff; Michael S Seaman; Kristine Swiderek; John P Moore; David Evans; James C Paulson; Chi-Huey Wong; Andrew B Ward; Ian A Wilson; Rogier W Sanders; Pascal Poignard; Dennis R Burton
Journal:  Immunity       Date:  2014-04-24       Impact factor: 31.745

7.  Using Split Luciferase Assay and anti-HSV Glycoprotein Monoclonal Antibodies to Predict a Functional Binding Site Between gD and gH/gL.

Authors:  Doina Atanasiu; Wan Ting Saw; Tina M Cairns; Roselyn J Eisenberg; Gary H Cohen
Journal:  J Virol       Date:  2021-01-27       Impact factor: 5.103

8.  Plasticity and Epitope Exposure of the HIV-1 Envelope Trimer.

Authors:  Rebecca L R Powell; Maxim Totrov; Vincenza Itri; Xiaomei Liu; Alisa Fox; Susan Zolla-Pazner
Journal:  J Virol       Date:  2017-08-10       Impact factor: 5.103

Review 9.  HIV broadly neutralizing antibody targets.

Authors:  Constantinos Kurt Wibmer; Penny L Moore; Lynn Morris
Journal:  Curr Opin HIV AIDS       Date:  2015-05       Impact factor: 4.283

10.  Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9.

Authors:  Jean-Philippe Julien; Jeong Hyun Lee; Albert Cupo; Charles D Murin; Ronald Derking; Simon Hoffenberg; Michael J Caulfield; C Richter King; Andre J Marozsan; Per Johan Klasse; Rogier W Sanders; John P Moore; Ian A Wilson; Andrew B Ward
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-20       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.